Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors

Author(s): He Jieyu, Tu Chao, Li Mengjun, Wang Shalong, Guan Xiaomei, Lin Jianfeng, Li Zhihong.

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 37 , 2012

Abstract:

Nampt/Visfatin/PBEF is a primary, rate-limiting enzyme involved in NAD+ biosynthesis, which serves as a pivotal substance for proteins, and is required for cell growth, survival, DNA replication and repair and energy metabolism. Growing researches have elucidated that it is a pleiotropic protein that functions not only as an enzyme, but also as an adipocytokin, a growth factor, and a cytokine. Additionally, accumulated evidences indicate that Nampt is correlated to various malignant tumors, and complicated mechanisms are proposed to be involved in the carcinogenesis, progression, invasion and metastasis of it, including regulation of energy metabolism and genome instability, promotion of proliferation, angiogenesis, and tumor-promoting inflammation, resistance in cell death and avoidance of immune destruction. APO866 and CHS-828 are recognized inhibitors of Nampt, known to block the intracellular and extracellular NAD+ synthesis pathway. Both of them are currently in clinical trials for the treatment of various malignant tumors and have been shown to represent novel promising antitumor chemotherapeutic agents.

Keywords: Nampt, visfatin, PBEF, malignant tumors, mechanism, angiogenesis, therapy, NAD+ biosynthesis, energy metabolism, clinical trials.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 37
Year: 2012
Page: [6123 - 6132]
Pages: 10
DOI: 10.2174/138161212803582531
Price: $58

Article Metrics

PDF: 20